Intel stock extends gains after report of possible U.S. government stake
Investing.com - Canaccord Genuity raised its price target on Taysha Gene Therapies (NASDAQ:TSHA) to $14.00 from $11.00 on Wednesday, while maintaining a Buy rating following the company’s second-quarter earnings report. The stock has shown remarkable momentum, gaining nearly 80% over the past six months, with analysts maintaining a Strong Buy consensus. According to InvestingPro data, analyst price targets range from $5.00 to $13.00, suggesting significant upside potential.
The research firm noted that Taysha’s Q2 2025 report was "largely uneventful" as the company’s TSHA-102 pivotal REVEAL Part B study remains on track with site activations in progress and patient enrollment expected to begin in the fourth quarter of 2025. InvestingPro analysis shows the company maintains a healthy financial position with a current ratio of 5.35, indicating strong ability to meet short-term obligations.
The REVEAL Part B trial is designed as a single-arm, open-label study where each patient serves as their own control, with the primary endpoint assessing the percentage of patients who gain or regain at least one developmental milestone after treatment with high-dose TSHA-102.
According to Canaccord, management indicated that the "statistical bar" for Part B requires approximately a 33% responder rate based on a null hypothesis of 6.7% in a study of 15 patients, compared to the 100% responder rate achieved in Part A of the study.
The research firm expressed confidence in a positive pivotal outcome and potential Biologics License Application (BLA) filing for possible approval and launch in late 2027, noting that Taysha is now capitalized through Phase 3 data following its May financing. While the company holds more cash than debt on its balance sheet, investors should note that InvestingPro analysis indicates the stock is trading above its Fair Value. Discover more insights and 8 additional ProTips for TSHA with an InvestingPro subscription, including detailed valuation metrics and growth forecasts.
In other recent news, Taysha Gene Therapies Inc . announced its financial results for the second quarter of 2025, reporting a revenue of $1.98 million. This figure exceeded analysts’ forecasts of $1.82 million, resulting in an 8.79% surprise. Despite this revenue beat, the company’s earnings per share (EPS) showed a loss of $0.09, slightly below the anticipated loss of $0.08. These financial results are part of the company’s latest developments, reflecting its ongoing fiscal performance. The revenue figures highlight an unexpected positive outcome, although the EPS results indicate challenges in profitability. Investors and analysts may find these results significant as they assess the company’s financial health. The recent earnings call provided insights into the company’s current financial standing and future expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.